Sugi Predict

Sugi Predict / Targets / RIN1

RIN1

Ras and Rab interactor 1 (Ras inhibitor JC99) · Q13671 · RIN1 on Sugi Atlas →

28,853 patent compounds predicted against RIN1, 19,620 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL143996 SCHEMBL143996 1.00 8/20
SCHEMBL143997 SCHEMBL143997 1.00 8/20
SCHEMBL381614 SCHEMBL381614 0.88 8/20
SCHEMBL25004 SCHEMBL25004 0.56 7/20
SCHEMBL192058 SCHEMBL192058 0.68 3/20
SCHEMBL121703 SCHEMBL121703 0.67 3/20
SCHEMBL192937 SCHEMBL192937 0.53 3/20
SCHEMBL121933 SCHEMBL121933 0.44 3/20
SCHEMBL29598 SCHEMBL29598 0.56 2/20
SCHEMBL94743 SCHEMBL94743 0.55 2/20
SCHEMBL95026 SCHEMBL95026 0.49 2/20
Didanosine Didanosine (SCHEMBL3364) 0.48 2/20
SCHEMBL224339 SCHEMBL224339 0.46 2/20
SCHEMBL256096 SCHEMBL256096 0.42 2/20
SCHEMBL385148 SCHEMBL385148 0.41 2/20
SCHEMBL386052 SCHEMBL386052 0.41 2/20
SCHEMBL270149 SCHEMBL270149 0.38 2/20
SCHEMBL472502 SCHEMBL472502 0.35 2/20
Biotin Biotin (SCHEMBL8763) 1.00 1/20
Biotin Biotin (SCHEMBL36572) 1.00 1/20

Clinical trials — most relevant to RIN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer PHASE1/PHASE2COMPLETED
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation PHASE2COMPLETED
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Expression and Function of the Renin-Angiotensin System in the Esophagus EARLY_PHASE1COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Identification of New Biomarkers of Insulin Resistance nanACTIVE_NOT_RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Rolandic Epilepsy Genomewide Association International Study nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
RASopathy Biorepository nanRECRUITING
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Insulin Detemir in Obesity Management nanACTIVE_NOT_RECRUITING
International PPB/DICER1 Registry nanRECRUITING
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Pubertal Development in Patients with RASopathies nanRECRUITING
Solid Tumors in RASopathies nanRECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RIN1 binder may also engage these)

ProteinNameSimilarity
Q921Q7 — 1.000 Q921Q7 →
P97680 — 0.999 P97680 →
Q9BRR9 — 0.988 Q9BRR9 →
Q8K330 — 0.987 Q8K330 →
A1L3T7 — 0.985 A1L3T7 →
O15211 — 0.985 O15211 →
Q80XI6 — 0.985 Q80XI6 →
Q9UQQ2 — 0.984 Q9UQQ2 →
CDC42BPG Serine/threonine-protein kinase MRCK gamma 0.984 landscape →
Q6ZVH7 — 0.983 Q6ZVH7 →
Q96MK2 — 0.983 Q96MK2 →
Q562E7 — 0.983 Q562E7 →
Q5TJE5 — 0.983 Q5TJE5 →
P58660 — 0.983 P58660 →
Q66HA1 — 0.982 Q66HA1 →
A0A8I3PMN2 — 0.982 A0A8I3PMN2 →
Q9BWT7 — 0.982 Q9BWT7 →
Q5FWH6 — 0.982 Q5FWH6 →
Q8CIE4 — 0.982 Q8CIE4 →
Q400G9 — 0.982 Q400G9 →
Q8IW93 — 0.982 Q8IW93 →
Q9JIR0 — 0.982 Q9JIR0 →
RAPGEF3 Rap guanine nucleotide exchange factor 3 0.982 landscape →
Q3UYR4 — 0.981 Q3UYR4 →
Q64355 — 0.981 Q64355 →
Q9BRG2 — 0.981 Q9BRG2 →
Q1JPD6 — 0.981 Q1JPD6 →
Q2LGB3 — 0.981 Q2LGB3 →
Q9NRS6 — 0.981 Q9NRS6 →
Q8R2S1 — 0.981 Q8R2S1 →